PL3102555T3 - Kompozycje związków i ich zastosowania - Google Patents

Kompozycje związków i ich zastosowania

Info

Publication number
PL3102555T3
PL3102555T3 PL15745995T PL15745995T PL3102555T3 PL 3102555 T3 PL3102555 T3 PL 3102555T3 PL 15745995 T PL15745995 T PL 15745995T PL 15745995 T PL15745995 T PL 15745995T PL 3102555 T3 PL3102555 T3 PL 3102555T3
Authority
PL
Poland
Prior art keywords
compositions
compounds
Prior art date
Application number
PL15745995T
Other languages
English (en)
Inventor
Jay Jie-Qiang Wu
Original Assignee
VM Oncology LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by VM Oncology LLC filed Critical VM Oncology LLC
Publication of PL3102555T3 publication Critical patent/PL3102555T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/10—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by doubly bound oxygen or sulphur atoms
    • C07D295/112—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by doubly bound oxygen or sulphur atoms with the ring nitrogen atoms and the doubly bound oxygen or sulfur atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • C07D295/116—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by doubly bound oxygen or sulphur atoms with the ring nitrogen atoms and the doubly bound oxygen or sulfur atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings with the doubly bound oxygen or sulfur atoms directly attached to a carbocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C15/00—Cyclic hydrocarbons containing only six-membered aromatic rings as cyclic parts
    • C07C15/20—Polycyclic condensed hydrocarbons
    • C07C15/27—Polycyclic condensed hydrocarbons containing three rings
    • C07C15/28—Anthracenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/04—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
    • C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D257/04—Five-membered rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/14—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D295/155—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
PL15745995T 2014-02-05 2015-02-05 Kompozycje związków i ich zastosowania PL3102555T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461936267P 2014-02-05 2014-02-05
EP15745995.9A EP3102555B1 (en) 2014-02-05 2015-02-05 Compositions of compounds and uses thereof
PCT/US2015/014592 WO2015120136A1 (en) 2014-02-05 2015-02-05 Compositions of compounds and uses thereof

Publications (1)

Publication Number Publication Date
PL3102555T3 true PL3102555T3 (pl) 2021-12-20

Family

ID=53754256

Family Applications (1)

Application Number Title Priority Date Filing Date
PL15745995T PL3102555T3 (pl) 2014-02-05 2015-02-05 Kompozycje związków i ich zastosowania

Country Status (22)

Country Link
US (3) US9346788B2 (pl)
EP (1) EP3102555B1 (pl)
JP (1) JP6197125B2 (pl)
KR (1) KR101723997B1 (pl)
CN (2) CN109820853B (pl)
AU (3) AU2015214185B2 (pl)
CA (1) CA2934043C (pl)
CY (1) CY1124416T1 (pl)
DK (1) DK3102555T3 (pl)
ES (1) ES2874533T3 (pl)
HR (1) HRP20210869T1 (pl)
HU (1) HUE055357T2 (pl)
LT (1) LT3102555T (pl)
MX (1) MX375372B (pl)
NZ (1) NZ721057A (pl)
PL (1) PL3102555T3 (pl)
PT (1) PT3102555T (pl)
RS (1) RS61968B1 (pl)
RU (1) RU2659068C1 (pl)
SI (1) SI3102555T1 (pl)
SM (1) SMT202100441T1 (pl)
WO (1) WO2015120136A1 (pl)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI2350075T1 (sl) 2008-09-22 2014-06-30 Array Biopharma, Inc. Substituirane imidazo (1,2b)piridazinske spojine kot Trk kinazni inhibitorji
CN102264736B (zh) 2008-10-22 2013-08-14 阵列生物制药公司 作为TRK激酶抑制剂的取代的吡唑并[1,5-a]嘧啶化合物
AR077468A1 (es) 2009-07-09 2011-08-31 Array Biopharma Inc Compuestos de pirazolo (1,5 -a) pirimidina sustituidos como inhibidores de trk- quinasa
BR122019024201B1 (pt) 2010-05-20 2021-08-03 Array Biopharma Inc Composto macrocíclico como inibidores de trk quinase, seu uso, e composição farmacêutica
CN109820853B (zh) * 2014-02-05 2022-05-10 Vm肿瘤药物有限责任公司 取代的杂环化合物在制备治疗癌症药物中的用途
TWI746426B (zh) 2014-11-16 2021-11-21 美商亞雷生物製藥股份有限公司 (S)-N-(5-((R)-2-(2,5-二氟苯基)-吡咯啶-1-基)-吡唑并[1,5-a]嘧啶-3-基)-3-羥基吡咯啶-1-甲醯胺硫酸氫鹽結晶型
EP3368039A1 (en) 2015-10-26 2018-09-05 The Regents of The University of Colorado, A Body Corporate Point mutations in trk inhibitor-resistant cancer and methods relating to the same
WO2017161235A1 (en) * 2016-03-18 2017-09-21 Purdue Pharma L. P. Process for preparing substituted 9,10-dioxo-9,10-dioxo-9,10-dihydroanthrecenes and 6h-anthra(1,9-cd)isoxazol-6-ones
UA125025C2 (uk) 2016-04-04 2021-12-29 Локсо Онколоджі, Інк. Способи лікування дитячих ракових захворювань
UA125026C2 (uk) 2016-04-04 2021-12-29 Локсо Онколоджі, Інк. РІДКІ КОМПОЗИЦІЇ (S)-N-(5-((R)-2-(2,5-ДИФТОРФЕНІЛ)ПІРОЛІДИН-1-ІЛ)ПІРАЗОЛО[1,5-a]ПІРИМІДИН-3-ІЛ)-3-ГІДРОКСИПІРОЛІДИН-1-КАРБОКСАМІДУ
MX392604B (es) 2016-05-18 2025-03-24 Array Biopharma Inc Procesos para la preparacion de (s)-n-(5-((r)-2-(2,5-difluorofenil)pirrolidin-1-il)-pirazolo[1,5-a]pirimidin-3-il)-3-hidroxipirrolidin-1-carboxamida y sales del mismo.
JOP20190092A1 (ar) 2016-10-26 2019-04-25 Array Biopharma Inc عملية لتحضير مركبات بيرازولو[1، 5-a]بيريميدين وأملاح منها
JOP20190213A1 (ar) 2017-03-16 2019-09-16 Array Biopharma Inc مركبات حلقية ضخمة كمثبطات لكيناز ros1
CA3080157A1 (en) 2017-10-26 2019-05-02 Array Biopharma Inc. Formulations of a macrocyclic trk kinase inhibitor
EP3773725A1 (en) 2018-03-29 2021-02-17 Loxo Oncology Inc. Treatment of trk-associated cancers
CN108972821B (zh) * 2018-09-06 2020-11-10 南京林业大学 一种秸秆刨花预处理液及其秸秆刨花板的制造方法
WO2020247758A1 (en) * 2019-06-07 2020-12-10 The Board Of Trustees Of The University Of Illinois Compounds and methods for the treatment of parasitic infections
EP3994142A4 (en) 2019-07-03 2023-09-06 Borah, Inc. CHEMICAL COMPOUNDS
WO2026162585A1 (en) * 2025-01-29 2026-08-06 AlzeCure Pharma AB Trka receptor modulators
WO2026162570A1 (en) * 2025-01-29 2026-08-06 AlzeCure Pharma AB Trka receptor modulators

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
GB8504253D0 (en) 1985-02-19 1985-03-20 Ici Plc Electrostatic spraying apparatus
DE3815221C2 (de) 1988-05-04 1995-06-29 Gradinger F Hermes Pharma Verwendung einer Retinol- und/oder Retinsäureester enthaltenden pharmazeutischen Zubereitung zur Inhalation zur Einwirkung auf die Schleimhäute des Tracheo-Bronchialtraktes einschließlich der Lungenalveolen
US5698155A (en) 1991-05-31 1997-12-16 Gs Technologies, Inc. Method for the manufacture of pharmaceutical cellulose capsules
RU2152944C1 (ru) * 1993-04-08 2000-07-20 Дзе Дюпон Мерк Фармасьютикал Компани Полициклические соединения, их производные, фармацевтические препараты как усилители и метод лечения нарушения мыслительной деятельности
IT1306704B1 (it) 1999-05-26 2001-10-02 Sirs Societa Italiana Per La R Anticorpi monoclonali e suoi derivati sintetici o biotecnologici ingrado di agire come molecole antagoniste per il ngf.
FR2807660A1 (fr) 2000-04-13 2001-10-19 Warner Lambert Co Utilisation d'antagonistes du ngf pour la prevention ou le traitement de douleurs viscerales chroniques
UA80447C2 (en) 2002-10-08 2007-09-25 Methods for treating pain by administering nerve growth factor antagonist and opioid analgesic
DK1575517T3 (da) 2002-12-24 2012-05-14 Rinat Neuroscience Corp Anti-ngf-antistoffer og fremgangsmåder til anvendelse af samme
UA97086C2 (uk) 2003-07-15 2012-01-10 Емджен, Інк. Виділене людське антитіло, яке специфічно зв'язується з фактором росту нервової тканини (ngf)
TW200523262A (en) * 2003-07-29 2005-07-16 Smithkline Beecham Corp Inhibitors of AKT activity
GB0326780D0 (en) 2003-11-18 2003-12-24 Imp College Innovations Ltd Biological materials and uses thereof
ITRM20030601A1 (it) 2003-12-24 2005-06-25 Lay Line Genomics Spa Metodo per l'umanizzazione di anticorpi e anticorpi umanizzati con esso ottenuti.
ITRM20050290A1 (it) 2005-06-07 2006-12-08 Lay Line Genomics Spa Uso di molecole in grado di inibire il legame tra ngf e il suo recettore trka come analgesici ad effetto prolungato.
ITRM20050332A1 (it) * 2005-06-24 2006-12-25 Lay Line Genomics Spa Uso di molecole in grado di bloccare l'attivita' di trka per potenziare gli effetti di analgesici oppiacei sul dolore.
EP2147310A4 (en) * 2007-04-27 2010-09-08 Univ Rochester COMPOSITIONS AND METHODS OF INHIBITING G-PROTEIN SIGNALING
RU2016116516A (ru) * 2008-12-08 2018-12-07 Мандифарма Интернэшнл Корпорейшн Лимитед Композиции ингибиторов тирозинкиназных рецепторов белков
BR112013021638A2 (pt) * 2011-02-25 2016-08-02 Irm Llc "compostos inibidores de trk, seu uso e composições que os compreendem"
EP2694509B1 (en) * 2011-04-05 2016-05-18 Pfizer Limited Pyrrolo[2,3-d]pyrimidine derivatives as inhibitors of tropomyosin-related kinases
CN109820853B (zh) * 2014-02-05 2022-05-10 Vm肿瘤药物有限责任公司 取代的杂环化合物在制备治疗癌症药物中的用途

Also Published As

Publication number Publication date
MX375372B (es) 2025-03-06
CN109820853B (zh) 2022-05-10
AU2018214064B2 (en) 2019-07-11
US20180078545A1 (en) 2018-03-22
CA2934043A1 (en) 2015-08-13
DK3102555T3 (da) 2021-08-09
CN106029614A (zh) 2016-10-12
CN109820853A (zh) 2019-05-31
AU2015214185A1 (en) 2016-06-30
EP3102555B1 (en) 2021-05-12
LT3102555T (lt) 2021-06-25
HRP20210869T1 (hr) 2021-08-20
EP3102555A4 (en) 2017-06-14
ES2874533T3 (es) 2021-11-05
AU2016213723A1 (en) 2016-09-08
SI3102555T1 (sl) 2021-11-30
JP2017505322A (ja) 2017-02-16
KR101723997B1 (ko) 2017-04-06
US20160228431A1 (en) 2016-08-11
RS61968B1 (sr) 2021-07-30
CN106029614B (zh) 2019-05-31
RU2659068C1 (ru) 2018-06-28
NZ721057A (en) 2023-04-28
US9346788B2 (en) 2016-05-24
CY1124416T1 (el) 2022-07-22
EP3102555A1 (en) 2016-12-14
CA2934043C (en) 2019-03-12
AU2018214064A1 (en) 2018-08-30
PT3102555T (pt) 2021-06-04
JP6197125B2 (ja) 2017-09-13
US20150218132A1 (en) 2015-08-06
SMT202100441T1 (it) 2021-09-14
US9855265B2 (en) 2018-01-02
AU2015214185B2 (en) 2016-08-04
HUE055357T2 (hu) 2021-11-29
BR112016016961A2 (pt) 2017-10-03
MX2016010053A (es) 2016-10-07
AU2016213723B2 (en) 2018-05-10
KR20160102569A (ko) 2016-08-30
WO2015120136A1 (en) 2015-08-13

Similar Documents

Publication Publication Date Title
SI3102555T1 (sl) Sestavki spojin in njihove uporabe
HUE056172T2 (hu) Szelenoorganikus vegyületeket tartalmazó készítmények és eljárások alkalmazásukra
ZA201701244B (en) Carrier-antibody compositions and methods of making and using the same
IL250568A0 (en) Anti-methanogenic preparations and their uses
SG11201609039QA (en) Compositions for mosquito control and uses of same
PL3218005T3 (pl) Związki oddziałujące z glikanami i sposoby ich zastosowania
IL264446A (en) Compounds and compositions and their use
PL3349743T3 (pl) Sposoby i kompozycje do hamowania oddziaływania dcn1-ubc12
IL235415A0 (en) Energetic substances and mixtures containing them
EP3190886A4 (en) Compositions and methods of use thereof
PL3113774T3 (pl) Kompozycje grapiprantu i sposoby ich zastosowania
IL234929A0 (en) Preparations containing liposomes and their use to prevent infections
EP3237413A4 (en) Compositions of fatostatin based heterocyclic compounds and uses thereof
SG10202100751YA (en) Compounds and compositions and uses thereof
ZA201700518B (en) Use of active compound compositions
EP3207029A4 (en) Tryptamide compositions and methods of use
IL253212A (en) Jasmonate derivatives and compositions thereof
IL247645A0 (en) Preparations of seleno-organic compounds and methods of using them
HK1231846A1 (en) Compositions of compounds and uses thereof
GB201418410D0 (en) use of compositions of matter
GB201412359D0 (en) Composition of objects
GB201412089D0 (en) Composition of objects
ZA201606358B (en) Compositions of selenoorganic compounds and methods and methods of use thereof
GB201502834D0 (en) Composition of objects
HK1233497A1 (en) Compositions of selenoorganic compounds and methods of use thereof